In summary, we analyzed the association between SNPs in the Fas/FasL signaling pathway and treatment outcomes including molecular response with 4.5 log reduction (MR4.5), following imatinib therapy in 187 Korean CML patients. The gene discussed is FAS; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.